In 2023, Chatterjee et al. evaluated the presence of plasma AD biomarkers in correlation to PET positivity for Aβ, investigating, in a transversal manner, the variations in Aβ1–42/Aβ1–40, P-Tau181, glial fibrillary acidic protein (GFAP), and Nfl along the continuum of AD [100]. This evidence concerns the gene GFAP and Alzheimer disease.